NCT05873374View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

August 31, 2024

Conditions

COVID-19 VaccineCOVID-19

Interventions

BIOLOGICAL

50 μg Baiya SARS-CoV-2 Vax 2

Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2

OTHER

Placebo

Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride

Trial Locations (1)

10330

Queen Saovabha Memorial Institute, Bangkok

All Listed Sponsors

lead

Baiya Phytopharm Co., Ltd.

INDUSTRY

NCT05873374 - Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19 | Biotech Hunter | Biotech Hunter